Bharat Biotech and Alopexx Team Up on Anti-Microbial Vaccines
Wednesday, 11 September 2024, 03:05
Bharat Biotech Partners with Alopexx
Bharat Biotech announced a significant collaboration with Alopexx Inc. to co-develop and commercialize a broad-spectrum anti-microbial vaccine known as AV0328. This vaccine aims to provide crucial public health interventions in India and various low-income countries.
Key Details of the Collaboration
- Upfront Payment: Alopexx will receive a one-time upfront payment for the collaboration.
- Milestone Payments: The agreement includes milestone payments linked to specific development targets.
- Royalties on Sales: Alopexx is set to earn royalties from future sales of the AV0328 vaccine in licensed territories.
The Impact on Public Health
This partnership underscores a vital step towards improving health outcomes through innovative vaccine solutions tailored for regions needing essential medical advancements.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.